Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 6Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × fluzoparib × Clear all
NCT04193319 2019-12-10

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡